BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Update

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 63,500 shares, an increase of 25.7% from the July 15th total of 50,500 shares. Based on an average daily volume of 35,700 shares, the short-interest ratio is currently 1.8 days.

BioStem Technologies Stock Performance

Shares of BioStem Technologies stock traded down 0.93 during trading on Thursday, hitting 12.62. 41,400 shares of the stock were exchanged, compared to its average volume of 26,303. The stock’s fifty day moving average is 9.07 and its 200 day moving average is 9.27. The stock has a market cap of $205.55 million, a PE ratio of 32.05 and a beta of 0.03. BioStem Technologies has a 12 month low of 1.21 and a 12 month high of 15.50.

BioStem Technologies (OTCMKTS:BSEM) last issued its quarterly earnings data on Monday, August 12th. The company reported 0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of 0.12 by 0.18. The business had revenue of 74.49 million during the quarter, compared to the consensus estimate of 43.99 million. Sell-side analysts anticipate that BioStem Technologies will post 0.49 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.